Literature DB >> 14739735

Barriers to the use of warfarin: potential solutions.

John H McAnulty1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14739735     DOI: 10.1023/B:JICE.0000011341.67214.2e

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


× No keyword cloud information.
  11 in total

1.  The use of oral anticoagulants (warfarin) in older people. American Geriatrics Society guideline.

Authors: 
Journal:  J Am Geriatr Soc       Date:  2002-08       Impact factor: 5.562

2.  Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators.

Authors:  R G Hart; L A Pearce; R M Rothbart; J H McAnulty; R W Asinger; J L Halperin
Journal:  J Am Coll Cardiol       Date:  2000-01       Impact factor: 24.094

3.  Generic warfarin: a cost-effective alternative to brand-name drug or a clinical wild card?

Authors:  J M DeCara; S Croze; R H Falk
Journal:  Chest       Date:  1998-02       Impact factor: 9.410

4.  Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators.

Authors: 
Journal:  JAMA       Date:  1998 Apr 22-29       Impact factor: 56.272

5.  Self-managed anticoagulation: results from a two-year prospective randomized trial with heart valve patients.

Authors:  P Sidhu; H O O'Kane
Journal:  Ann Thorac Surg       Date:  2001-11       Impact factor: 4.330

6.  Benefits of a mobile, point-of-care anticoagulation therapy management program.

Authors:  James M Gill; Mark K Landis
Journal:  Jt Comm J Qual Improv       Date:  2002-11

7.  Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial.

Authors:  Charles W Francis; Bruce L Davidson; Scott D Berkowitz; Paul A Lotke; Jeffrey S Ginsberg; Jay R Lieberman; Anne K Webster; James P Whipple; Gary R Peters; Clifford W Colwell
Journal:  Ann Intern Med       Date:  2002-10-15       Impact factor: 25.391

8.  Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

Authors:  Paul M Ridker; Samuel Z Goldhaber; Ellie Danielson; Yves Rosenberg; Charles S Eby; Steven R Deitcher; Mary Cushman; Stephan Moll; Craig M Kessler; C Gregory Elliott; Rolf Paulson; Turnly Wong; Kenneth A Bauer; Bruce A Schwartz; Joseph P Miletich; Henri Bounameaux; Robert J Glynn
Journal:  N Engl J Med       Date:  2003-02-24       Impact factor: 91.245

9.  Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio.

Authors:  Gerald A Banet; Amy D Waterman; Paul E Milligan; Susan K Gatchel; Brian F Gage
Journal:  Chest       Date:  2003-02       Impact factor: 9.410

10.  Fixed-dose versus adjusted-dose warfarin in patients with prosthetic heart valves in a peri-urban impoverished population.

Authors:  Biddy Buchanan-Leel; Basil N Levetan; Carl J Lombard; Patrick J Commerford
Journal:  J Heart Valve Dis       Date:  2002-07
View more
  1 in total

1.  Transitions of care in anticoagulated patients.

Authors:  Franklin Michota
Journal:  J Multidiscip Healthc       Date:  2013-06-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.